Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
about
Molecular regulation of miRNAs and potential biomarkers in the progression of hepatic steatosis to NASHMetabolic syndrome and its predictors in an urban population in Kenya: A cross sectional study.Calcium Reduces Liver Injury in Mice on a High-Fat Diet: Alterations in Microbial and Bile Acid Profiles.Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy.Profile of Free Fatty Acids and Fractions of Phospholipids, Cholesterol Esters and Triglycerides in Serum of Obese Youth with and without Metabolic Syndrome.Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children.Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms.The pharmacological management of NAFLD in children and adolescents.Circadian rhythms of liver physiology and disease: experimental and clinical evidence.Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review.Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients.Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease.Combination of Hypertension Along with a High Fat and Cholesterol Diet Induces Severe Hepatic Inflammation in Rats via a Signaling Network Comprising NF-κB, MAPK, and Nrf2 Pathways.The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease.Knockout of l-Histidine Decarboxylase Prevents Cholangiocyte Damage and Hepatic Fibrosis in Mice Subjected to High-Fat Diet Feeding via Disrupted Histamine/Leptin Signaling.Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.Negative hepatic computed tomographic attenuation pattern in a dog with vacuolar hepatopathy and hepatic fat accumulation secondary to cushing's syndrome.Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine.Unexpected metabolic disorders induced by endocrine disruptors in Xenopus tropicalis provide new lead for understanding amphibian decline.Folate and B12 Levels Correlate with Histological Severity in NASH Patients.Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease.Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway
P2860
Q26778376-0AF2B32F-073B-47C4-8F74-83FBDB14AC6EQ33869151-F96FB728-2B27-487B-8921-5414DBA3B770Q36194038-AB797CE0-D154-4270-BFFB-11326CBD5FD6Q36411014-B88421F5-7000-4E4F-8D52-39D9286D9FEEQ36633228-55572215-0681-42E3-908D-3C25F7B3E2D8Q36853284-59E74D6A-6C13-448D-81C9-28B1F4FA768AQ36900196-3A053A02-E23E-42C5-8DEE-5C9E5221FC4CQ38642318-ED407829-E2FE-4635-81C3-7EF7C0A2166DQ38643266-3A0C4E6A-DCAC-4DD8-8BE6-BBDE9A12233FQ38747400-2090F4B3-96D1-435D-893B-B51D5B9F1489Q39341139-A5DF4A98-2829-429C-A00F-02E125915185Q40241316-630411A1-63D4-493D-95B4-597FA0DE6C5AQ41449920-7AC4E9B1-13AA-4AF2-BDF2-4C300A76975EQ41706840-645ADEB5-C1C1-428A-9CAB-FBFF714F7A76Q42368251-8E47A952-D1F2-4A50-9F88-119EFC70819CQ46606052-F11A6B6A-820D-4878-93BB-0235861DB5A5Q47676902-8D8F1306-28FE-41A5-AF40-62A09CADF513Q47768810-191DA332-3E5F-47CC-8FA7-402CF7070A11Q47850897-692B2E28-F6EC-47B0-91B9-D08DFB884C2AQ48159180-34392520-C835-487E-B708-D835B654CC82Q49373886-E1BBE53E-4C7F-469B-B68E-C03C07830DDAQ50872061-25FC324D-54E5-4C2D-A0A7-8BBD57FAA05BQ52568660-D9793655-7999-4BBA-8E5C-1B24E3890898Q54972685-CF66CA26-A512-4980-B48F-74B4C725C540Q55054211-8508931B-7CE0-4E4B-8B0B-3EC7B63A04BBQ58804681-7B51A245-980B-4210-AE6C-A356D2550691
P2860
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@ast
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@en
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@nl
type
label
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@ast
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@en
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@nl
prefLabel
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@ast
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@en
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@nl
P2860
P1476
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
@en
P2093
Toshio Fukusato
Yoshihisa Takahashi
P2860
P304
15539-15548
P356
10.3748/WJG.V20.I42.15539
P407
P577
2014-11-01T00:00:00Z